• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over

    2/19/25 8:00:00 AM ET
    $SWTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SWTX alert in real time by email

    - Educational campaign aims to raise awareness and drive conversation about desmoid tumors, the devastating impact they have on patients' lives -

    STAMFORD, Conn., Feb. 19, 2025 /PRNewswire/ -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, and Jennifer Fisher, jewelry designer and desmoid tumor patient advocate, are collaborating to increase understanding of desmoid tumors as well as to encourage patients to find a specialist, like an oncologist with experience treating desmoid tumors who can discuss available treatment options to manage their desmoid tumor.

    Desmoid tumors are aggressive and invasive tumors that can arise in any part of the body.1,2 Their tendril-like growths can wrap around nearby tissue and compress vital organs and nerves.2-4 This can cause severe and chronic pain, loss of function, reduced mobility, disfigurement, and anxiety, all of which can profoundly diminish a person's health and quality of life.1-3,5-7 Desmoid tumors are most commonly diagnosed in patients between the ages of 20 and 44 years and have a two-to-three times higher prevalence in females.8-9 

    "I was diagnosed with a desmoid tumor on my chest wall when I was 30 years old. I had so many questions, no answers, and didn't know what to expect for my future," said Jennifer. "Having a desmoid tumor was an emotional journey for me but it also shaped who I am today. I am passionate about sharing my story and proud to be working with SpringWorks to encourage others to seek expert care for their desmoid tumor and not let the physical pain from these tumors rob them of their vitality."  

    At the time of Jennifer's diagnosis, there were no approved treatments for desmoid tumors. Initially her doctors recommended that Jennifer have the tumor surgically removed, which would have taken half of her left chest wall with the possibility of permanently losing mobility in her arm. 

    "Since desmoid tumors have a high rate of recurrence after surgery, treatment guidelines now recommend systemic therapies for most desmoid tumors that are growing and/or symptomatic," stated Dr. Alessandra Maleddu, Sarcoma Specialist, University of Colorado. "As science continues to evolve, it's important for patients with desmoid tumors to be aware of the latest treatments available and to talk to their doctor about non-surgical options."

    People living with a desmoid tumor should closely track how their symptoms are impacting daily life to gauge if their desmoid tumor could be progressing. Having increased pain or not being able to keep up with everyday activities could be signs that it is time to take action. Individuals should speak to a specialist, like an oncologist with experience treating desmoid tumors, and advocate to find the best approach for treatment.10

    "Our commitment to the desmoid tumor community runs deep, and we are pleased that Jennifer is sharing her powerful story to raise awareness about these devastating tumors and encourage patients to take action to manage their desmoid tumor," said Bhavesh Ashar, Chief Commercial Officer at SpringWorks Therapeutics. "Jennifer's experience shines a light on the many struggles that patients with desmoid tumors face and underscores the importance of patients advocating for themselves and finding the right care team to determine the best approach for their treatment."

    Follow Jennifer Fisher on Instagram.

    About Desmoid Tumors

    Desmoid tumors are rare, aggressive, locally invasive tumors of the soft tissues that can be serious, debilitating, and, in rare cases when vital structures are impacted, life-threatening.1,2

    Desmoid tumors are most commonly diagnosed in patients between the ages of 20 and 44 years, with a two-to-three times higher prevalence in females.8,9 It is estimated that there are 1,000-1,650 new cases diagnosed per year in the United States.8,11,12

    Although they do not metastasize, desmoid tumors can be associated with recurrence rates of up to 77% after surgical resection.9,13 Desmoid tumor experts and treatment guidelines now recommend systemic therapies as first-line intervention instead of surgery for most tumor locations requiring treatment.10,14

    About SpringWorks Therapeutics

    SpringWorks is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with severe rare diseases and cancer. We developed and commercialized the first and only FDA-approved therapy for adults with progressing desmoid tumors and the first and only FDA-approved medicine for both adults and children with symptomatic neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN) not amenable to complete resection. We are also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers.

    For more information, visit www.springworkstx.com and follow @SpringWorksTx on X, LinkedIn, Facebook, Instagram, and YouTube.

    Contact

    Media:

    Catherine Cantone

    Corporate Communications Sr. Director

    [email protected]

    (203) 705-1126

    References

    1. Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives. Pathologica. 2021;113(2):70-84. doi:10.32074/1591-951X-213.
    2. Penel N, Chibon F, Salas S. Adult desmoid tumors: biology, management and ongoing trials. Curr Opin Oncol. 2017;29(4):268-274. doi:10.1097/CCO.0000000000000374.
    3. Constantinidou A, Scurr M, Judson I, Litchman C. Clinical presentation of desmoid tumors. In: Litchman C, ed. Desmoid Tumors. Springer; 2012:chap 2. Accessed August 2023. https://www.researchgate.net/publication/226455135. doi:10.1007/978-94-007-1685-8_2.
    4. Joglekar SB, Rose PS, Sim F, Okuno S, Petersen I. Current perspectives on desmoid tumors: the Mayo Clinic approach. Cancers (Basel). 2011;3(3):3143-3155. doi:10.3390/cancers3033143.
    5. Husson O, Younger E, Dunlop A, et al. Desmoid fibromatosis through the patients' eyes: time to change the focus and organisation of care? Support Care Cancer. 2019;27(3):965-980. doi:10.1007/s00520-018-4386-8.
    6. Gounder MM, Maddux L, Paty J, Atkinson TM. Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis. Cancer. 2020;126(3):531-539. doi:10.1002/cncr.32555.
    7.  Bektas, M, et al.  Desmoid Tumors: A Comprehensive Review. Adv Therapeutics 2023. doi.org/10.1007/s12325-023-02592-0.
    8. van Broekhoven DLM, Grünhagen DJ, den Bakker MA, van Dalen T, Verhoef C. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol. 2015;22(9):2817-2823. doi:10.1245/s10434-015-4632-y.
    9. Skubitz KM. Biology and treatment of aggressive fibromatosis or desmoid tumor. Mayo Clin Proc. 2017;92(6):947-964. doi:10.1016/j.mayocp.2017.02.012.
    10. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed August 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
    11. Orphanet Report Series: Rare Diseases collection. Prevalence and incidence of rare diseases: bibliographic data. Number 1, January 2022. Accessed November 5, 2024. https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf. 
    12. U.S. Department of Commerce. News Blog. U.S. population estimated at 332,403,650 on Jan. 1, 2022. Accessed August 2023. https://www.commerce.gov/news/ blog/2022/01/us-population-estimated-332403650-jan-1-2022#:~.
    13. Easter DW, Halasz NA. Recent trends in the management of desmoid tumors. Summary of 19 cases and review of the literature. Ann Surg. 1989;210(6):765-769. doi:10.1097/00000658-198912000-00012.
    14. Gronchi A, et al. Desmoid Tumor Working Group. The management of desmoid tumours: a joint global consensus-based guideline approach for adult and pediatric patients. Eur J Cancer. 2020;127:96-107. doi:10.1016/j.ejca.2019.11.013.

    SpringWorks Therapeutics

    Photo of Jennifer Fisher

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/springworks-therapeutics-and-jewelry-designer-jennifer-fisher-team-up-to-encourage-people-with-desmoid-tumors-to-take-action-before-their-tumor-takes-over-302379560.html

    SOURCE SpringWorks Therapeutics

    Get the next $SWTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SWTX

    DatePrice TargetRatingAnalyst
    11/20/2024$60.00Outperform
    Evercore ISI
    2/5/2024$75.00Buy
    Guggenheim
    12/1/2022$45.00Buy
    BofA Securities
    9/8/2021$97.00 → $105.00Overweight
    JP Morgan
    8/5/2021$136.00 → $137.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SWTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Edris Badreddin sold $1,084,592 worth of shares (20,000 units at $54.23), decreasing direct ownership by 11% to 169,712 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      3/5/25 6:33:49 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Islam Saqib covered exercise/tax liability with 30,756 shares and sold $2,657,656 worth of shares (49,000 units at $54.24), decreasing direct ownership by 8% to 954,869 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      3/5/25 6:32:29 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Islam Saqib sold $1,768,401 worth of shares (29,328 units at $60.30), decreasing direct ownership by 3% to 1,034,625 units (SEC Form 4)

      4 - SpringWorks Therapeutics, Inc. (0001773427) (Issuer)

      2/24/25 6:58:58 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Merck KGaA, Darmstadt, Germany to Acquire SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

      – Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany's Healthcare business – – SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas – – Planned acquisition will strengthen the presence of Merck KGaA, Darmstadt, Germany's Healthcare business in

      4/28/25 2:13:33 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business

      Purchase price of $47 per share in cash represents an enterprise value of €3.0 billion ($3.4 billion), or an equity value of approximately $3.9 billion Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for the Healthcare business of Merck KGaA, Darmstadt, Germany SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas Planned acquisition will strengthen the presence of the Healthcare business of Merck KGaA, Darmstadt, Germany, i

      4/28/25 2:11:00 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

      STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company anticipates the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) will adopt an opinion on the marketing authorization application (MAA) for nirogacestat, an oral gamma secretase inhibitor, for the treatment of adults with desmoid tumors in the second quarter of 2025. About SpringWorks Therapeutics SpringWorks is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with severe rare diseases an

      4/27/25 10:35:13 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc.

      SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      10/25/24 9:46:32 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc. (Amendment)

      SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      2/14/24 6:41:08 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SpringWorks Therapeutics Inc. (Amendment)

      SC 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      2/14/24 8:56:14 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on SpringWorks Therapeutics with a new price target

      Evercore ISI initiated coverage of SpringWorks Therapeutics with a rating of Outperform and set a new price target of $60.00

      11/20/24 8:20:27 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on SpringWorks Therapeutics with a new price target

      Guggenheim initiated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $75.00

      2/5/24 8:04:18 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BofA Securities initiated coverage on SpringWorks Therapeutics with a new price target

      BofA Securities initiated coverage of SpringWorks Therapeutics with a rating of Buy and set a new price target of $45.00

      12/1/22 7:57:05 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • November 27, 2023 - FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors

      For Immediate Release: November 27, 2023 Today, the U.S. Food and Drug Administration approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. Desmoid tumors are non-cancerous but can be locally aggressive. The tumor

      11/27/23 5:34:21 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for OGSIVEO issued to SPRINGWORKS THERAPEUTICS INC

      Submission status for SPRINGWORKS THERAPEUTICS INC's drug OGSIVEO (ORIG-1) with active ingredient NIROGACESTAT has changed to 'Approval' on 11/27/2023. Application Category: NDA, Application Number: 217677, Application Classification: Type 1 - New Molecular Entity

      11/27/23 5:34:04 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    Leadership Updates

    Live Leadership Updates

    See more
    • SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

      STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the appointment of Martin Mackay, Ph.D. to the Company's Board of Directors. Dr. Mackay is a highly accomplished research and development (R&D) executive with more than 30 years of pharmaceutical and biotech R&D experience, including leadership roles at Pfizer, AstraZeneca and Alexion. "Martin is a proven industry leader whose experience in developing and delivering novel treatments to patients in need is exceptional," said Saqib Islam, Chief Executive Officer of SpringWorks. "His expertise

      7/29/24 6:30:11 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer

      STAMFORD, Conn., Sept. 11, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Tai-An Lin, Ph.D., as its Chief Scientific Officer. Dr. Lin brings more than 25 years of biotechnology and global pharmaceutical experience in advancing drug discovery programs from target identification through early clinical trials across the therapeutic areas of oncology, immuno-oncology, and immunology. "Tai-An is a talented scientist with a strong track record of advancing innovative oncology programs from discovery

      9/11/23 6:30:00 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

      STAMFORD, Conn., July 15, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the appointment of Carlos Albán to the Company's Board of Directors. Mr. Albán, who served as Vice Chairman and Chief Commercial Officer at AbbVie, Inc. ("AbbVie") until his retirement last year, brings over 30 years of experience in global commercial strategy and operations. "Carlos' success in building and leading global commercial organizations will be valuable as SpringWorks continues its planned transition into a commercial-stage compa

      7/15/22 6:30:00 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    SEC Filings

    See more
    • SEC Form 10-Q filed by SpringWorks Therapeutics Inc.

      10-Q - SpringWorks Therapeutics, Inc. (0001773427) (Filer)

      5/9/25 4:17:26 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by SpringWorks Therapeutics Inc.

      SCHEDULE 13G/A - SpringWorks Therapeutics, Inc. (0001773427) (Subject)

      5/7/25 11:01:53 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by SpringWorks Therapeutics Inc.

      DEFA14A - SpringWorks Therapeutics, Inc. (0001773427) (Filer)

      4/28/25 4:02:03 PM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SWTX
    Financials

    Live finance-specific insights

    See more
    • SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

      – Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively – – Received FDA approval of GOMEKLI™ (mirdametinib) for the treatment of adult and pediatric patients with symptomatic NF1-PN not amendable to complete resection – – Ended 2024 with $461.9 million in cash, cash equivalents and marketable securities – STAMFORD, Conn., Feb. 20, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial results for the fourth quarter and full year periods ended December 31, 2024 and provi

      2/20/25 6:30:32 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 20, 2025

      STAMFORD, Conn., Jan. 30, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, February 20, 2025 to report its fourth quarter and full year financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcas

      1/30/25 7:00:50 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

      – Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highlight further reductions in tumor size, increase in ORR, sustained improvement in desmoid tumor symptoms, and consistent safety profile – – Granted FDA Priority Review on NDA and received validation of EU Marketing Authorization Application for mirdametinib for the treatment of adults and children with NF1-PN – – $498 million in cash, cash equivalents and marketable securities as of September 30, 2024; expected to fund the Company through profitability, which is anticipated in the first

      11/12/24 6:30:21 AM ET
      $SWTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care